TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02101021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Momelotinib
Description: Tablet (s) administered orally once or twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match momelotinib
Description: Placebo to match momelotinib tablets administered orally once or twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Intravenously administered over approximately 30-40 minutes or as per institutional standard of care on Days 1, 8, and 15 of each cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nab-paclitaxel
Description: Intravenously administered over approximately 30-40 minutes or as per institutional standard of care on Days 1, 8, and 15 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Intravenously administered over approximately 30 minutes or as per institutional standard of care on Days 1, 8, and 15 of each cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine
Description: Intravenously administered over approximately 30 minutes or as per institutional standard of care on Days 1, 8, and 15 of each cycle
Study: NCT02383095

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Art therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: metacognitive therapy
Study: NCT01166100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine Hydrochloride
Description: Fluoxetine Hydrocloride Delayed Release Capsules, 90 mg of Dr. Reddy's Laboratories.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine Hydrochloride
Description: Fluoxetine Hydrocloride Delayed Release Capsules, 90 mg of Dr. Reddy's Laboratories.
Study: NCT03078712

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral Perfusion guided resuscitation
Description: Sequential approach with fluids (guided by dynamic predictors of fluid responsiveness), vasopressors titration, and inodilators according to peripheral perfusion.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lactate guided resuscitation
Description: Sequential approach with fluids (guided by dynamic predictors of fluid responsiveness), vasopressors titration, and inodilators according to lactate decrease.
Study: NCT03694613

Intervention type: OTHER
Group type: OTHER
Intervention: Placental/Umbilical Cord Blood sample
Description: After infant is delivered, placenta along with clamped umbilical cord Blood will be obtained from the ObGyn team. One umbilical clamp will be placed at the umbilical end, and the other clamp will be placed on the placental end of the umbilical cord. Then the umbilical cord will be cut between the clamps. The umbilical cord will be cleaned three times with 2% chlorhexidine, plus 70% isopropyl alcohol under sterile conditions (sterile gloves). Cord blood samples will be collected using vacutainer blood collecting system with a sterile 22-gauge needle. We will collect 3 - 4 ml of blood.
Study: NCT02632721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 836858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 836858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 836858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 836858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 836858
Study: NCT02663271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be given at 10mg/kg IV every 2 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optune
Description: Optune will be worn continuously for 12 months. Optune is programmed by Novocure to deliver 200 kHz TTFields in two sequential, perpendicular field directions at a maximal intensity of 707mARMS. There will be no adjustments made to the device by investigators or patients/caregivers.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain MRI
Description: Brain MRI will be done at screening and every 8 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of Life Questionnaires
Description: The quality of life questionnaires will be performed within 14 days of treatment and every 4 weeks.
Study: NCT00272064

Intervention type: DRUG
Group type: OTHER
Intervention: Insulin glulisine
Description: individualized, once daily, dose aiming at 2h post-prandial plasma glucose goal \< 140 mg/dl (7.8 mmol/l) in the optimized treatment phase, since visit 3, subcutaneous

Intervention type: DRUG
Group type: OTHER
Intervention: Insulin glulisine
Description: individualized, once daily, dose aiming at 2h post-prandial plasma glucose goal \< 140 mg/dl (7.8 mmol/l) in the optimized treatment phase, since visit 3, subcutaneous

Intervention type: DRUG
Group type: OTHER
Intervention: Insulin glargine
Description: individualized, once daily, dose to reach mean fasting plasma glucose (FPG) \<= 126 mg/dl (7.0 mmol/l), since randomization, subcutaneous

Intervention type: DRUG
Group type: OTHER
Intervention: Insulin glargine
Description: individualized, once daily, dose to reach mean fasting plasma glucose (FPG) \<= 126 mg/dl (7.0 mmol/l), since randomization, subcutaneous

Intervention type: DRUG
Group type: OTHER
Intervention: Metformin
Description: 1000 mg b.i.d, since the qualification phase, oral

Intervention type: DRUG
Group type: OTHER
Intervention: Metformin
Description: 1000 mg b.i.d, since the qualification phase, oral
Study: NCT02527525

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stepped Care
Study: NCT01578486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salsalate
Description: open-label trial of salsalate 3g/day for 12 weeks.
Study: NCT01292629

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iSert 251 intraocular lens
Description: aphakic intraocular lens
Study: NCT04292899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: Administered as an intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: Administered as an intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: Administered as an intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: Administered as an intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of Care Treatment for COVID-19 Infection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of Care Treatment for COVID-19 Infection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of Care Treatment for COVID-19 Infection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of Care Treatment for COVID-19 Infection
Study: NCT02763670

Intervention type: OTHER
Group type: OTHER
Intervention: PRETICARD patient care management
Description: A standardized and specialized network to take care of the severe cardiac insufficiency:~* An initial assessment and consultations with health professionals specialized in severe cardiac insufficiency during the hospitalization for cardiac insufficiency~* At 1 months, consultations and acts realized by health professionals specialized (one hospital day care)~* At 2 months, a therapeutic education program for heart failure patients, approved by the Rhône-Alpes regional public health authorities (week hospital: two days and one night).~* At 6 and 18 months, one cardiology consultation~* At 12 and 24 months, consultations and acts realized by health professionals specialized (one hospital day care)

Intervention type: OTHER
Group type: OTHER
Intervention: As usual  patient care management
Description: Conventional management of heart failure patients is defined in the guide HAS (Haute Autorité de Santé) care course. Patient follow-up, however, is defined by the patient's physician and / or cardiologist at the waning of his hospitalization, according to the usual practice for patients with stage II, III or IV NYHA.~According to these recommendations, the patient should see his cardiologist at least once a year.~Usual practices are:~* An initial assessment and consultations with health professionals specialized in severe cardiac insufficiency during the hospitalization for cardiac insufficiency~* At 12 months, a cardiologic consultation. For the study, three evaluation points are programmed: two by phone at 6 and 18 months, two by a consultation at 24 months. This interview aimed to evaluate the number of hospitalization, consultations and acts realized by health professionals specialized (the information in the logbook).
Study: NCT03950297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 609A
Description: 609A is a recombinant anti-PD-1 humanized IgG4 kappa antibody that targets the human PD-1
Study: NCT02657161

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RABIPUR®
Description: Biological rabies vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PIKA rabies vaccine
Description: Biological rabies vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PIKA rabies vaccine with an accelerated regimen
Description: Biological rabies vaccine
Study: NCT03514342

Intervention type: PROCEDURE
Intervention: Interscalene brachial plexus block
Description: Under ultrasound guidance, the 5th to 7th cervical nerve roots are identified between anterior and middle scalene muscles and subsequently blocked.

Intervention type: DRUG
Intervention: 0.75% ropivacaine
Description: Placement of 25 to 30 ml of 0.75% ropivacaine around the 5th to 7th cervical nerve roots
Study: NCT01557933

Intervention type: OTHER
Intervention: No interventions will be used
Description: No interventions will be used
Study: NCT03843281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: s. above

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: s. above

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: s. above

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine
Description: s. above
Study: NCT02031783

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mixture of glucose and fructose

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: glucose
Study: NCT00353834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Exenetide 5ug twice daily for 4 weeks, then 10ug twice daily for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glargine Insulin
Description: Glargine insulin 10-20 units once daily and subsequently adjusted per protocol to achieve a fasting glucose of 100mg/dl and avoid hypoglycemia.
Study: NCT01927185

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Long Axis strategy
Description: With the long-axis approach the vein appeared in the longitudinal view. With this approach only the vein was visible on the screen. The needle was held at a 30° angle, oriented in-plane with the transducer and the skin punctured at the base of the transducer. The vessel alignment was maintained during the procedure and the entire length of the needle was visible during the progression through the tissues.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Short Axis Strategy
Description: With the short-axis approach the probe was positioned almost perpendicularly to the clavicle. The needle was held at an angle of 45° relative to the skin surface and sagittal to the plane of the probe (out-of-plane). During the progression to the vessel, the visualization of the needle was limited to the deformation of tissue and artefacts produced by needle advancement. When the tip abutted the vein wall, additional pressure produced transient vessel deformation, which disappeared once the wall was penetrated.
Study: NCT02973087

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: von Willebrand factor (Recombinant)
Description: OD participants will receive intravenous (IV) rVWF:RCo at an initial prophylactic dose of 50 +/- 10 International Unit per Kilogram (IU/kg) twice (two infusions) a week for at least 12 months up to 15 months and may be increased up to 80 IU/kg. pdVWF switch cohort participants will receive rVWF:RCo equivalent (± 10%) to the weekly VWF dose received during prophylactic treatment with pdVWF.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Antihemophilic Factor (Recombinant)
Description: During prophylaxis period any bleeding episodes requiring substitution therapy with VWF concentrate to control bleeding will be treated with rVWF with or without ADVATE. Participants will receive rFVIII IV if necessary for OD treatment of breakthrough bleeds or for peri-operative. The dose will be according to the bleeding type and severity and it will be adjusted to the clinical response.
Study: NCT00656773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: 0.15 μg/kg, IV following by 0.075 μg/kg every 3 minutes during 15 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: 0.15 mg/kg, IV following by 0.075 mg/kg every 3 minutes during 15 minutes
Study: NCT05556278

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound study
Description: based on the recommendations of the American Association of Electrodiagnostic Medicine (AAEM) (1)

Intervention type: DIAGNOSTIC_TEST
Intervention: Neurophysiological test
Description: ultrasound protocol described by Chen et al. (2)
Study: NCT01518283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel 10 mg/m2
Description: Cabazitaxel 10 mg/m2 in a 1-hour infusion on days 1, 8, 15 and 22 of 5-week cycles.
Study: NCT02290626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elmental diet
Description: elemental diet is administered using PEG.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semi-solid diet
Description: Semi-solid diet is administered using PEG.
Study: NCT01184222

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: great occipital nerve stimulation
Description: * Active Comparator: Arm Active SENGO The patients will be hospitalised and managed by medication withdrawal and active GONS, surgically temporarily implanted.~* Arm sham SENGO : The patients will be hospitalised and managed by medication withdrawal and sham GONS, surgically temporarily implanted.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: great occipital nerve stimulation
Description: * Active Comparator: Arm Active SENGO The patients will be hospitalised and managed by medication withdrawal and active GONS, surgically temporarily implanted.~* Arm sham SENGO : The patients will be hospitalised and managed by medication withdrawal and sham GONS, surgically temporarily implanted.
Study: NCT01536951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3009104
Description: administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: moxifloxacin
Description: Administered orally
Study: NCT04960020

Intervention type: OTHER
Intervention: Retrospective Data Review
Description: Retrospective Data Review
Study: NCT02492477

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: evaluation of PORT-A-CATH®
Description: in patients in curative setting, clinical assessment, PORT-A-CATH® testing of possibility of saline-administration and blood withdrawal with vacutainer, laboratory assessment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: evaluation of PORT-A-CATH®
Description: in patients in curative setting, clinical assessment, PORT-A-CATH® testing of possibility of saline-administration and blood withdrawal with vacutainer, laboratory assessment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: blocking with Medunasal®-Heparinblock
Description: blocking of the functioning PORT-A-CATH® with heparinized 0,9% NaCl solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: blocking with Medunasal®-Heparinblock
Description: blocking of the functioning PORT-A-CATH® with heparinized 0,9% NaCl solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: restoration of PORT-A-CATH® with Alteplase
Description: by malfunction of the PORT-A-CATH® attempting of restoration with Actilyse® according to guidelines

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: restoration of PORT-A-CATH® with Alteplase
Description: by malfunction of the PORT-A-CATH® attempting of restoration with Actilyse® according to guidelines
Study: NCT01506960

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InfraReDx Lipiscan IVUS
Description: Near Infrared Spectroscopy/Intravascular Ultrasound will be performed following OCT imaging.
Study: NCT01817751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valproic acid
Description: Given by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sildenafil citrate
Description: Given by mouth
Study: NCT00514163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine + S-1
Description: gemcitabine on day one and 8th S-1 po days 1 to14 every 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine
Description: gemcitabine DIV on day one , 8th and 15th
Study: NCT01773642

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral intervention to support pediatric HIV disclosure
Study: NCT01721876

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching Volasertib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volasertib
Description: Volasertib

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cytarabine
Description: Cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine
Study: NCT02849197

Intervention type: PROCEDURE
Intervention: surgery for pilonidal sinus disease
Description: surgical treatment of pilonidal sinus disease via primary closure, Limberg flap0 technique and Modified Limberg flap technique.

Intervention type: PROCEDURE
Intervention: surgery for pilonidal sinus disease
Description: surgical treatment of pilonidal sinus disease via primary closure, Limberg flap0 technique and Modified Limberg flap technique.

Intervention type: PROCEDURE
Intervention: surgery for pilonidal sinus disease
Description: surgical treatment of pilonidal sinus disease via primary closure, Limberg flap0 technique and Modified Limberg flap technique.
Study: NCT01473563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Administered intravenously
Study: NCT01235793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: The DRBEAT regimen will be similar to RBEAM. Rituximab and Carmustine will be given Day -6. Etoposide and Cytarabine will be given on Days -5 to -2. Temozolomide will be given via divided doses over five days starting on Day -5 to Day -1. A dose escalation design, known as EWOC (Escalation with overdose control) will be used to determine the target dose of temozolomide for this study. The starting dose given over five days will begin at 250mg/m2 (cumulative total dose of 1250 mg/m2), as previous data indicates this to be a safe dose. Based on the reported Dose Limiting toxicities from the previous patients, the EWOC statistical modeling will be performed to determine the next dose level.
Study: NCT01191866

Intervention type: BEHAVIORAL
Intervention: psychosocial intervention
Description: The interventions will include an art therapist, a social worker and volunteer work under the supervision of a diabetes nurse. These therapies will be given to selected patients based on individual needs. We will use existing questionnaires in order to identify problematic areas and quantify quality of life
Study: NCT01537536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EndoTAG-1
Description: EndoTAG-1 (22 mg/m2 liposomal paclitaxel) + Paclitaxel (70 mg/m2) Weekly i.v. infusions of EndoTAG-1 and paclitaxel for 12 weeks followed by subsequent treatment with the standard FEC regimen (Fluorouracil 500 mg/m2, Epirubicin 100 mg/m2, Cyclophosphamide 500 mg/m2) once every 3 weeks for 3 cycles of therapy followed by surgery.
Study: NCT00578136

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Bupivacaine, 0.25%, dose amount is weight based, injection is divided per dise with rectus sheath injection or with local infiltration of the operative area.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Bupivacaine, 0.25%, dose amount is weight based, injection is divided per dise with rectus sheath injection or with local infiltration of the operative area.
Study: NCT01202279

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Guaifenesin
Description: 1200 mg guaifenesin and 120 mg pseudoephedrine HCl bid for 7 days

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo bid for 7 days
Study: NCT03970850

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: NeuMoDx CT/NG Assay
Description: NeuMoDx CT/NG Assay as implemented on NeuMoDx 288 Molecular System and NeuMoDx 96 Molecular System

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: NeuMoDx CT/NG Assay
Description: NeuMoDx CT/NG Assay as implemented on NeuMoDx 288 Molecular System and NeuMoDx 96 Molecular System

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: FDA-cleared NAATs
Description: Testing swabs and urine specimen from both male and female subjects on the FDA-cleared NAATs
Study: NCT01177683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Phase I component:~Bendamustine escalating cohorts to determine MTD, IV over 1 hour, Days 1 and 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Phase I and II components:~Pegylated liposomal doxorubicin, 30 mg/m2 IV over 1 hour, Day 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Phase I and II components:~Bortezomib 1.3 mg/m2 IV bolus, Days 1, 4, 8, and 11

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Phase II component:~Bendamustine at at MTD IV over 1 hour, Days 1 and 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Phase II component:~Filgrastim (if defined in MTD) 5 µg/kg/day SC, starting day 6 until neutrophil recovery to ANC \>1000